Background: Cancer, particularly breast cancer, poses a significant global health challenge, driving an increasing demand for chemotherapy. Paclitaxel, a widely used chemotherapeutic agent, is primarily metabolized by the cytochrome P450 enzymes CYP2C8 and CYP3A4, generating metabolites such as 6α-hydroxypaclitaxel and p-3-hydroxypaclitaxel. Although these metabolites lack pharmacological activity, paclitaxel metabolism influences both efficacy and toxicity, necessitating the need for accurate monitoring of both drug and metabolite levels.,Objectives: To develop and validate a robust, selective, rapid and sensitive LC-MS/MS method for the simultaneous quantification of paclitaxel, 6α-hydroxypaclitaxel, and p-3-hydroxypaclitaxel in human plasma.,Methods: Chromatographic and mass spectrometric conditions were optimized and validated according to FDA guidelines.,Results: A rapid LC-MS/MS method was developed with a total run time of 5 minutes. Lower limits of quantification (LLOQ) were 2.5 nM for paclitaxel and 5 nM for both metabolites. The method demonstrated excellent linearity, precision, accuracy, and sensitivity, with calibration standards and quality control samples meeting acceptance criteria. The method was highly selective, with no significant interference from plasma components or the co-administered drug, trastuzumab.,Conclusion: A robust and sensitive LC-MS/MS method for the quantification of paclitaxel and its two major metabolites in human plasma was successfully developed and validated. The improved sensitivity, particularly the lower LLOQ for paclitaxel, represents an advantage over previous analytical approaches. This assay is suitable for pharmacokinetic studies and may support individualized chemotherapy optimization, particularly in underrepresented populations such as those in sub-Saharan Africa.